Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carla M Nester

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Kidney International Reports|February 24, 2025
Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 GlomerulopathyCarla M Nester, Ute Eisenberger, Alexandre Karras, et al.
Lancet (London, England)|September 28, 2025
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 studyDavid Kavanagh, Andrew S Bomback, Marina Vivarelli, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 14, 2026
Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis: Phase 3 VALIANT Subgroup AnalysisMarina Vivarelli, Gema Ariceta, Yael Borovitz, et al.
Frontiers in Immunology|June 2, 2025
Factor H-related 1 and heparan sulfate architecture contribute to complement dysregulation in C3 glomerulopathyAmanda K Slagle, Nicolo Ghiringhelli Borsa, Kai Wang, et al.
Nature Reviews. Nephrology|January 30, 2019
C3 glomerulopathy - understanding a rare complement-driven renal diseaseRichard J H Smith, Gerald B Appel, Anna M Blom, et al.
Kidney International Reports|April 18, 2023
Pregnancy History and Kidney Disease Progression Among Women Enrolled in Cure GlomerulonephropathyMonica L Reynolds, Andrea L Oliverio, Jarcy Zee, et al.
Pediatric Nephrology (Berlin, Germany)|March 11, 2021
Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes-a Pediatric Nephrology Research Consortium studyMelissa Muff-Luett, Keia R Sanderson, Rachel M Engen, et al.
Kidney International|August 22, 2024
An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working GroupCarla M Nester, David L Feldman, Richard Burwick, et al.
Biorxiv : the Preprint Server for Biology|June 22, 2026
Monoclonal nephritic factors reveal insights into C3 convertase dynamics and dysregulationSeth J Welsh, Christopher T Culek, Zhen Xu, et al.
The New England Journal of Medicine|December 3, 2025
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGNFadi Fakhouri, Andrew S Bomback, Gema Ariceta, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Kidney International Reports|February 24, 2025
Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 GlomerulopathyCarla M Nester, Ute Eisenberger, Alexandre Karras, et al.
Lancet (London, England)|September 28, 2025
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 studyDavid Kavanagh, Andrew S Bomback, Marina Vivarelli, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 14, 2026
Pegcetacoplan for Adolescents with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis: Phase 3 VALIANT Subgroup AnalysisMarina Vivarelli, Gema Ariceta, Yael Borovitz, et al.
Frontiers in Immunology|June 2, 2025
Factor H-related 1 and heparan sulfate architecture contribute to complement dysregulation in C3 glomerulopathyAmanda K Slagle, Nicolo Ghiringhelli Borsa, Kai Wang, et al.
Nature Reviews. Nephrology|January 30, 2019
C3 glomerulopathy - understanding a rare complement-driven renal diseaseRichard J H Smith, Gerald B Appel, Anna M Blom, et al.
Kidney International Reports|April 18, 2023
Pregnancy History and Kidney Disease Progression Among Women Enrolled in Cure GlomerulonephropathyMonica L Reynolds, Andrea L Oliverio, Jarcy Zee, et al.
Pediatric Nephrology (Berlin, Germany)|March 11, 2021
Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes-a Pediatric Nephrology Research Consortium studyMelissa Muff-Luett, Keia R Sanderson, Rachel M Engen, et al.
Kidney International|August 22, 2024
An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working GroupCarla M Nester, David L Feldman, Richard Burwick, et al.
Biorxiv : the Preprint Server for Biology|June 22, 2026
Monoclonal nephritic factors reveal insights into C3 convertase dynamics and dysregulationSeth J Welsh, Christopher T Culek, Zhen Xu, et al.
The New England Journal of Medicine|December 3, 2025
Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGNFadi Fakhouri, Andrew S Bomback, Gema Ariceta, et al.
Pageof 7